Seer, Inc.
HealthcareNASDAQ:SEER · NASDAQ Global Select
+$0.02 today
Vol 0.10M · Avg 0.33M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$73.6M +15.0% | -$86.6M -0.4% | -$86.3M +7.2% | -$93.0M -30.6% | -$71.2M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $7.2M +17.3% | $6.2M +10.7% | $5.6M +41.5% | $3.9M +54.1% | $2.6M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 -100.0% | $1.2M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $15.4M -45.4% | $28.2M -18.1% | $34.4M +2.2% | $33.7M +29.9% | $25.9M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$579.0K -302.1% | -$144.0K +94.7% | -$2.7M +61.6% | -$7.1M -20.9% | -$5.9M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $277.0K -43.1% | $487.0K +61.3% | $302.0K +110.5% | -$2.9M -15.2% | -$2.5M | $592.6M | $1.3B | $626.2M |
| Inventory | -$2.9M -8.7% | -$2.7M -37.0% | -$1.9M -22.5% | -$1.6M +55.8% | -$3.6M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $1.1M -68.3% | $3.4M +439.9% | -$987.0K +36.4% | -$1.6M -196.9% | $1.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $983.0K +174.6% | -$1.3M -1348.4% | -$91.0K +91.5% | -$1.1M +22.2% | -$1.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $7.1M +13.1% | $6.3M +162.1% | -$10.1M -706.0% | $1.7M +65.3% | $1.0M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$44.4M +3.6% | -$46.1M +21.9% | -$59.1M +2.8% | -$60.8M -31.1% | -$46.3M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$1.8M +49.9% | -$3.6M +51.0% | -$7.3M +28.8% | -$10.3M -48.3% | -$6.9M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $164.0M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$173.2M +36.6% | -$272.9M +32.3% | -$403.1M -10.1% | -$366.3M -30.8% | -$280.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $237.8M -30.5% | $342.0M -23.7% | $448.3M +76.7% | $253.6M +118.7% | $116.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$1.3M -478.7% | $343.0K | $0 -100.0% | $170.0K +100.1% | -$164.0M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $61.5M -6.5% | $65.9M +73.7% | $37.9M +130.9% | -$122.7M +28.2% | -$170.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $458.0K | $0 | $0 | $0 -100.0% | $103.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$10.2M +13.7% | -$11.8M -90792.3% | -$13.0K +35.0% | -$20.0K +42.9% | -$35.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$827.0K -357.6% | $321.0K -31.0% | $465.0K -88.1% | $3.9M -71.5% | $13.7M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$10.6M +8.1% | -$11.5M -2643.1% | $452.0K -88.4% | $3.9M -96.7% | $116.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $6.5M -20.9% | $8.3M +139.9% | -$20.7M +88.5% | -$179.6M -78.5% | -$100.6M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$46.2M +6.9% | -$49.7M +25.1% | -$66.4M +6.6% | -$71.0M -33.4% | -$53.3M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
$841.97M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$245.42M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
PepGen Inc.
NASDAQ:PEPG
$101.68M
MediciNova, Inc.
NASDAQ:MNOV
$60.54M
Generation Bio Co.
GBIO
$35.98M
Anebulo Pharmaceuticals, Inc.
ANEB
$15.91M
HCW Biologics Inc.
HCWB
$2.67M
SEC Filings
Recent regulatory filings
No filings found.
Does SEER generate free cash flow?
Seer, Inc. (SEER) generated -$46,245,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does SEER produce?
Operating cash flow was -$44,448,000.00, before capital expenditures of $1.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.